Farther Finance Advisors LLC Boosts Holdings in Pacira BioSciences, Inc. $PCRX

Farther Finance Advisors LLC raised its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 1,503.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,160 shares of the company’s stock after purchasing an additional 7,651 shares during the period. Farther Finance Advisors LLC’s holdings in Pacira BioSciences were worth $195,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. US Bancorp DE raised its position in shares of Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after buying an additional 537 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Pacira BioSciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after buying an additional 1,165 shares during the last quarter. Brooklyn Investment Group raised its position in shares of Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock valued at $56,000 after buying an additional 1,764 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Pacira BioSciences by 112.8% in the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company’s stock valued at $92,000 after buying an additional 1,958 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Pacira BioSciences in the first quarter valued at about $51,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

Shares of PCRX opened at $25.27 on Thursday. Pacira BioSciences, Inc. has a 1-year low of $14.91 and a 1-year high of $27.64. The stock has a market cap of $1.14 billion, a PE ratio of -9.09 and a beta of 0.41. The firm has a 50-day simple moving average of $25.17 and a two-hundred day simple moving average of $24.86. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The business had revenue of $181.10 million during the quarter, compared to analysts’ expectations of $183.11 million. During the same period last year, the business earned $0.96 earnings per share. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, analysts forecast that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, Director Marcelo Bigal sold 4,912 shares of Pacira BioSciences stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the sale, the director directly owned 11,393 shares in the company, valued at $269,672.31. This trade represents a 30.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PCRX shares. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Truist Financial upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Friday, July 25th. Finally, Wall Street Zen upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Pacira BioSciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.40.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.